AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
🇳🇬
Candesartan Cilexetil; Hydrochlorothiazide in Nigeria
5 products registered with NAFDAC — 5 active
| Brand / Product | Reg. No. | Holder | Status | Expires |
|---|---|---|---|---|
| Necsartan Tablets Tablet | A4-9507 | Nectar Healthcare Limited | active | 20 Dec 2028 |
| Advantec Tablets 16 mg + 12.5 mg** Tablet | A4-9124 | Getz Pharma Nigeria Limited | active | 24 May 2028 |
| Candesartan/HCT Sandoz 8 mg/12.5 mg Tablets (check pack size) Tablet | B4-3523 | Novartis Nigeria Limited | active | 1 Dec 2026 |
| Atacand Plus 16/12.5 Tablets** Tablet | A4-1470 | AstraZeneca Nigeria Limited | active | 27 Oct 2026 |
| Candesartan/HCT Sandoz 16 mg/12.5 mg Tablets** Tablet | B4-3524 | Novartis Nigeria Limited | active | 8 Feb 2026 |
Candesartan Cilexetil; Hydrochlorothiazide — NAFDAC Registration Details
NAFDAC (Nigeria) has 5 registered products containing Candesartan Cilexetil; Hydrochlorothiazide, of which 5 are currently active. Data is sourced directly from the official NAFDAC drug register and refreshed daily.
Track Candesartan Cilexetil; Hydrochlorothiazide registration expiry dates, monitor competitor approvals, and receive alerts when registration status changes. Create a free account to set up portfolio monitoring.